Evidence map›Paper›PMID 27582125›Full record

ArticleMethods (San Diego, Calif.)2017

Total cellular protein presence of the transcription factor IRF8 does not necessarily correlate with its nuclear presence.

Hans Minderman, Orla Maguire, Kieran L O'Loughlin, Jason Muhitch, Paul K Wallace, Scott I Abrams

Open access · greenAbstract read
In one paragraph

Article in Methods (San Diego, Calif.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Hans MindermanFlow and Image Cytometry Shared Resource, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, United States. Electronic address: hans.minderman@roswellpark.org.
Orla MaguireFlow and Image Cytometry Shared Resource, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, United States.
Kieran L O'LoughlinFlow and Image Cytometry Shared Resource, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, United States.
Jason MuhitchDept of Urology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, United States.
Paul K WallaceFlow and Image Cytometry Shared Resource, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, United States.
Scott I AbramsDept of Immunology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, United States.
Roswell Park Comprehensive Cancer Center · US

Funding

Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dean G. Tang · 1985 to 2026
$116.6M
Institutional Career DevelopmentKL2TR001413 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI DUBOCOVICH, MARGARITA L · 2015 to 2024
$4.2M
Associate-Director Flow and Image Cytometry Roswell Park ComprehensiveCancer CenterR50CA211108 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI HANS MINDERMAN · 2016 to 2026
$3.0M
Mechanisms Underlying Functional Programs of Tumor-Associated MacrophagesR01CA172105 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ABRAMS, SCOTT I. · 2015 to 2019
$2.0M
IRF-8 as a Negative Regulator of CD11b+Gr-1+ Myeloid Cell Production and FunctionR01CA140622 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI ABRAMS, SCOTT I. · 2011 to 2015
$2.0M
Imaging Flow CytometerS10OD018048 · OD · ROSWELL PARK CANCER INSTITUTE CORP · PI MINDERMAN, HANS · 2014 to 2014
$400k
NCATS NIH HHS KL2 TR001413NCI NIH HHS P30 CA016056NCI NIH HHS R01 CA140622NCI NIH HHS R01 CA172105NCI NIH HHS R50 CA211108NIH HHS S10 OD018048
6 · The paper itself

Abstract

The transcription factor interferon regulatory factor-8 (IRF8) plays an essential role in myeloid differentiation and lineage commitment, based largely on molecular and genetic studies. The detection of IRF8 in specific cell populations by flow cytometry (FCM) has the potential to provide new insights into normal and pathologic myelopoiesis, but critical validation of this protein-based approach, particularly in human samples, is lacking. In this study, the assessment of total cellular IRF8 presence was compared to its specific nuclear presence as assessed by imaging flow cytometry (IFC) analysis. Peptide neutralization of the IRF8-specific antibody that has been predominantly used to date in the literature served as a negative control for the immunofluorescent labeling. Expression of total IRF8 was analyzed by total cellular fluorescence analogous to the mean fluorescence intensity readout of conventional FCM. Additionally, specific nuclear fluorescence and the similarity score between the nuclear image (DAPI) and the corresponding IRF8 image for each cell were analyzed as parameters for nuclear localization of IRF8. IFC showed that peptide blocking eliminated binding of the IRF8 antibody in the nucleus. It also reduced cytoplasmic binding of the antibody but not to the extent observed in the nucleus. In agreement with the similarity score data, the total cellular IRF8 as well as nuclear IRF8 intensities decreased with peptide blocking. In healthy donor peripheral blood subpopulations and a positive control cell line (THP-1), the assessment of IRF8 by total cellular presence correlated well with its specific nuclear presence and correlated with the known distribution of IRF8 in these cells. In clinical samples of myeloid-derived suppressors cells derived from patients with renal carcinoma, however, total cellular IRF8 did not necessarily correlate with its nuclear presence. Discordance was primarily associated with peptide blocking having a proportionally greater effect on the IRF8 nuclear localization versus total fluorescence assessment. The data thus indicate that IRF8 can have cytoplasmic presence and that during disease its nuclear-cytoplasmic distribution may be altered, which may provide a basis for potential myeloid defects during certain pathologies.

Indexed as

AntibodiesCarcinomaCase-Control StudiesCell DifferentiationCell NucleusCytoplasmFlow CytometryGene ExpressionHematopoiesisHumansImage CytometryInterferon Regulatory Factor-8Interferon Regulatory FactorsKidney NeoplasmsMyeloid CellsPeptidesAntibodiesInterferon Regulatory Factor-8Interferon Regulatory FactorsPeptidesImaging flow cytometry intracellular localizationIRF8

Identifiers

PMID27582125
PMCPMC5545900
OpenAlexW2508469870

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.